Cargando…

FGFR1 and WT1 are markers of human prostate cancer progression

BACKGROUND: Androgen-independent prostate adenocarcinomas are responsible for about 6% of overall cancer deaths in men. METHODS: We used DNA microarrays to identify genes related to the transition between androgen-dependent and androgen-independent stages in the LuCaP 23.1 xenograft model of prostat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Devilard, Elizabeth, Bladou, Franck, Ramuz, Olivier, Karsenty, Gilles, Dalès, Jean-Philippe, Gravis, Gwenaëlle, Nguyen, Catherine, Bertucci, François, Xerri, Luc, Birnbaum, Daniel
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698935/ https://www.ncbi.nlm.nih.gov/pubmed/17137506 http://dx.doi.org/10.1186/1471-2407-6-272

Ejemplares similares

Systemic treatment for metastatic prostate cancer
por: Gravis, Gwenaelle
Publicado: (2019)

Nectin-3 (CD113) Interacts with Nectin-2 (CD112) to Promote Lymphocyte Transendothelial Migration
por: Devilard, Elisabeth, et al.
Publicado: (2013)

Solitary Fibrous Tumor of the Prostate: Case Report and Review of the Literature
por: Moureau-Zabotto, Laurence, et al.
Publicado: (2012)

Intrinsic FGFR2 and Ectopic FGFR1 Signaling in the Prostate and Prostate Cancer
por: Wang, Cong, et al.
Publicado: (2019)

Gene Expression Profiling for In Silico Microdissection of Hodgkin's Lymphoma Microenvironment and Identification of Prognostic Features
por: Bertucci, François, et al.
Publicado: (2011)

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer
por: Jacquemier, Jocelyne, et al.
Publicado: (2009)

XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
por: Birnbaum, David Jérémie, et al.
Publicado: (2019)

Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: Prominent expression of P-cadherin
por: Ben Hamida, Azza, et al.
Publicado: (2008)

DNAM-1 and PVR Regulate Monocyte Migration through Endothelial Junctions
por: Reymond, Nicolas, et al.
Publicado: (2004)

Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation.
por: Xerri, L., et al.
Publicado: (1998)

Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men
por: Touzani, Rajae, et al.
Publicado: (2019)

Predicting Gleason Score of Prostate Cancer Patients Using Radiomic Analysis
por: Chaddad, Ahmad, et al.
Publicado: (2018)

WT1 peptide analogue WT1-126Y enhances leukemia lysis
por: Alqudaihi, Ghofran, et al.
Publicado: (2014)

XPO1, therapeutic … and prognostic target in sarcomas
por: Bertucci, François, et al.
Publicado: (2016)

Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
por: Oji, Yusuke, et al.
Publicado: (2016)

WT1-AS promotes cell apoptosis in hepatocellular carcinoma through down-regulating of WT1
por: Lv, Long, et al.
Publicado: (2015)

Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
por: Cabel, Luc, et al.
Publicado: (2017)

The Evaluation of FGFR1, FGFR2 and FOXO1 in Orofacial Cleft Tissue
por: Goida, Jana, et al.
Publicado: (2022)

Editorial: WT1 in Development and Disease
por: Chau, You-Ying, et al.
Publicado: (2022)

Prognostic value of PDL1 expression in pancreatic cancer
por: Birnbaum, David J., et al.
Publicado: (2016)

Long term efficacy of WT1 peptide vaccine in patients with WT1 overexpressing hematopoeitic and solid malignancies
por: Letsch, Anne, et al.
Publicado: (2013)

Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017)

WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
por: Oji, Yusuke, et al.
Publicado: (2023)

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
por: Gallo, Leandro H.
Publicado: (2021)

Implications of the Wilms’ Tumor Suppressor Wt1 in Cardiomyocyte Differentiation
por: Wagner, Nicole, et al.
Publicado: (2021)

Role for first zinc finger of WT1 in DNA sequence specificity: Denys–Drash syndrome-associated WT1 mutant in ZF1 enhances affinity for a subset of WT1 binding sites
por: Wang, Dongxue, et al.
Publicado: (2018)

FGFR1 regulates proliferation and metastasis by targeting CCND1 in FGFR1 amplified lung cancer
por: Yang, Ying, et al.
Publicado: (2020)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
por: Rochigneux, Philippe, et al.
Publicado: (2018)

Myeloproliferative disorder FOP-FGFR1 fusion kinase recruits phosphoinositide-3 kinase and phospholipase Cγ at the centrosome
por: Lelièvre, Hélène, et al.
Publicado: (2008)

Microstructure and Hot Deformation Behavior of the Mg–8 wt.% Sn–1.5 wt.% Al Alloy
por: Sun, Zhaoqian, et al.
Publicado: (2021)

WT1 regulates angiogenesis in Ewing Sarcoma
por: Katuri, Varalakshmi, et al.
Publicado: (2014)

Genomic Organization of the Human WT1 Gene
por: Tadokoro, Keiko, et al.
Publicado: (1992)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Targeted Disruption of the Intracellular Domain of Receptor FgfrL1 in Mice
por: Bluteau, Gilles, et al.
Publicado: (2014)

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer
por: Daulat, Avais M., et al.
Publicado: (2019)

Identification of a Novel C-Terminal Truncated WT1 Isoform with Antagonistic Effects against Major WT1 Isoforms
por: Tatsumi, Naoya, et al.
Publicado: (2015)

WT1 Gene Mutations, rs16754 Variant, and WT1 Overexpression as Prognostic Factors in Acute Myeloid Leukemia Patients
por: Koczkodaj, Dorota, et al.
Publicado: (2022)

A WT1-positive pleural neoplasm. Is it always a mesothelioma?: Diagnostic pitfall of WT1 immunohistochemistry in pleural neoplasm
por: Gaggero, G, et al.
Publicado: (2023)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7vngn16e8m8b3aitbrg2frsh4s